OraSure Technologies reported Q1 2024 revenue of $54.1 million. The company is undergoing restructuring initiatives expected to result in $15 million of annualized expense reductions and aims to achieve cash flow breakeven for its core business by the end of 2024. They also delivered initial orders for Syphilis Health Check™ as part of their distribution agreement with Diagnostics Direct.
Total net revenues for Q1 2024 decreased by 65% to $54.1 million compared to $155.0 million in Q1 2023.
Core revenue (excluding COVID-19 revenue) was $31.0 million, a 15% decrease year-over-year.
COVID-19 revenue decreased by 80% year-over-year to $23.1 million.
GAAP gross margin percentage was 44.5% compared to 42.5% in the same period last year.
The Company is guiding to Q2 2024 revenue of $50 to $55 million, which includes core revenue of $33 to $36 million and InteliSwab® revenue of $17 to $19 million. Our Q2 2024 guidance includes approximately $650 thousand of revenue from the Diversigen business that we plan to exit.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance